Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CSF1R |
| Variant | mutant |
| Impact List | unknown |
| Protein Effect | unknown |
| Gene Variant Descriptions | CSF1R mutant indicates an unspecified mutation in the CSF1R gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
CSF1R mutant |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01831726 | Phase II | Dovitinib | Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | Completed | USA | 0 |
| NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Trastuzumab + Tucatinib Futibatinib Ipilimumab + Nivolumab Palbociclib Talazoparib Dabrafenib + Trametinib Temsirolimus Pertuzumab + Trastuzumab Trastuzumab deruxtecan Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 1 |
| NCT07539441 | Phase Ib/II | Mirdametinib | A Study of Mirdametinib in People With Central Nervous System Tumors | Recruiting | USA | 0 |
| NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus) | Recruiting | FRA | 0 |